Tarsus Pharmaceuticals (NASDAQ:TARS) Director William Phd Link Sells 12,500 Shares of Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Director William Phd Link sold 12,500 shares of the business’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $68.79, for a total value of $859,875.00. Following the transaction, the director owned 116,332 shares in the company, valued at approximately $8,002,478.28. This trade represents a 9.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Tarsus Pharmaceuticals Trading Down 2.2%

Shares of NASDAQ:TARS opened at $68.24 on Thursday. Tarsus Pharmaceuticals, Inc. has a 1 year low of $38.51 and a 1 year high of $85.25. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.85 and a quick ratio of 3.82. The firm has a market capitalization of $2.90 billion, a P/E ratio of -42.12 and a beta of 0.55. The business’s 50-day moving average is $69.59 and its 200 day moving average is $70.20.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings data on Monday, February 23rd. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.01). The company had revenue of $151.67 million during the quarter, compared to analysts’ expectations of $144.56 million. Tarsus Pharmaceuticals had a negative net margin of 14.72% and a negative return on equity of 19.63%. On average, research analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on TARS. Lifesci Capital upgraded Tarsus Pharmaceuticals to a “strong-buy” rating in a research note on Monday. Zacks Research lowered Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 25th. Guggenheim raised their price objective on Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $68.00 target price on shares of Tarsus Pharmaceuticals in a report on Thursday, February 5th. Finally, Oppenheimer upped their target price on Tarsus Pharmaceuticals from $95.00 to $105.00 and gave the company an “outperform” rating in a research report on Wednesday, February 25th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $91.83.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. RTW Investments LP boosted its holdings in Tarsus Pharmaceuticals by 5.0% in the fourth quarter. RTW Investments LP now owns 3,335,320 shares of the company’s stock valued at $273,096,000 after purchasing an additional 157,884 shares during the last quarter. Deep Track Capital LP lifted its holdings in shares of Tarsus Pharmaceuticals by 71.4% in the 3rd quarter. Deep Track Capital LP now owns 3,000,000 shares of the company’s stock valued at $178,290,000 after buying an additional 1,250,000 shares during the period. Jennison Associates LLC lifted its holdings in shares of Tarsus Pharmaceuticals by 5.5% in the 3rd quarter. Jennison Associates LLC now owns 2,604,580 shares of the company’s stock valued at $154,790,000 after buying an additional 136,582 shares during the period. Vanguard Group Inc. boosted its stake in shares of Tarsus Pharmaceuticals by 5.6% in the fourth quarter. Vanguard Group Inc. now owns 2,399,560 shares of the company’s stock worth $196,476,000 after buying an additional 127,470 shares during the last quarter. Finally, Morgan Stanley boosted its stake in shares of Tarsus Pharmaceuticals by 6.7% in the fourth quarter. Morgan Stanley now owns 2,040,742 shares of the company’s stock worth $167,096,000 after buying an additional 128,340 shares during the last quarter. 90.01% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Tarsus Pharmaceuticals

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Lifesci Capital upgraded TARS to “Strong‑Buy” and issued a string of estimates that narrow expected losses for FY2026 (Lifesci: -$1.01 vs. consensus -$3.17) and project smaller quarterly losses earlier in the year plus a positive Q4‑2026 EPS of $0.09 — a bullish signal that likely lifted the stock. MarketBeat TARS coverage
• Neutral Sentiment: Broad analyst sentiment remains mixed-to‑favorable: the stock has an average recommendation of “Moderate Buy,” so Lifesci’s view improves the outlook but does not yet represent unanimous analyst conviction. Article Title
• Negative Sentiment: Director William J. Link sold 12,500 shares at an average of $68.79 (disclosed 3/16), reducing his stake by ~9.7% — an insider sale that can create short‑term selling pressure or signal profit‑taking. SEC Form 4

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.